**CASE REPORT**

**Intracanalicular meningioma: diagnostic by immunohistochemistry**

Andrei Borin ¹, Daniel Mochida Okada ², Oswaldo Laércio Mendonça Cruz ³

Facial paralysis House-Brackmann grade IV presented postoperatively. Histology reported a tumor compatible with meningothelial meningioma, which was confirmed by immunohistochemistry (S-100 - negative; EMA - positive). Audiometry was done 15 days later, demonstrating that hearing was preserved (PTA - 62.5dB). The patient recovered from facial paralysis, which had decreased to grade II six months postoperatively.

**DISCUSSION**

Differentiating MEs from VSs may be difficult when MEs are exclusively IC. Both tumors affect similar age groups (45-55 yrs) and predominate in females. They also present with similar signs and symptoms, such as hearing loss and tinnitus. Facial paralysis may occur in up to 27% of ICME cases; it is, however, less common in ICVSs (about 3%).¹² Facial paralysis may be credited to differences in methodology.²³ Radiological differentiation between both tumors is generally not possible.¹³ ICME surgery has certain peculiarities. Compared to ICVSs, ICMEs tend to adhere more and to be more vascularized; they may also occupy various portions of the internal acoustic canal.¹ Such lack of predictability in the location of ICME and its relation with the VII and VIII cranial nerves may significantly increase the difficulty of surgery; the facial nerve may be displaced by the tumor to any of the quadrants in the internal acoustic canal, increasing the possibility of iatrogenic injuries.¹² We defended and demonstrated the possibility of preserving postoperative hearing, as defined by the “Committee on Hearing and Equilibrium of the American Academy of Otolaryngology - Head & Neck Surgery.”⁴ The real possibility of preserving hearing, however, is still uncertain in ICME cases, given the paucity of case reports. Immunohistochemistry is useful in differentiating these tumors. MEs may express both epithelial and mesenchymal markers, reflecting their double embryological origin or mesenchymal cell totipotentiality. Many markers have been used, although there is wide variation of results in the literature, which may be credited to differences in methodology.³ The “epithelial membrane antigen” (EMA) is generally strongly positive in MEs (84%) and negative or weakly positive and with a focal pattern in VSs. Protein S-100 is not a specific marker for neuroectodermal tissue; it may be positive in 28% of MEs.² Vimentin is positive in about 95% of MEs.² Table 1 shows the main immunohistochemical findings in posterior fossa tumors, based on studies by Winnek and Radley.¹² Electron microscopic ultra-structural studies should be reserved for difficult cases not clarified by immunohistochemistry, given the high cost and the technical difficulties of this method.

**REFERENCES**


**Table 1. Main immunoreactive features for differentiating posterior fossa tumors.**

<table>
<thead>
<tr>
<th>TUMOR</th>
<th>Vimentin</th>
<th>EMA</th>
<th>keratin</th>
<th>S-100</th>
<th>GFAP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Meningioma</td>
<td>+</td>
<td>+</td>
<td>+/- (a)</td>
<td>+/- (b)</td>
<td>-</td>
</tr>
<tr>
<td>Schwannoma</td>
<td>+</td>
<td>+/- (c)</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>glioma</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>carcinoma</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+/-</td>
<td>-</td>
</tr>
<tr>
<td>melanoma</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>cordoma</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
</tr>
</tbody>
</table>

(a) - positive in secretory meningiomas
(b) - positive in 15%
(c) - in general weak and focal when positive

Key: EMA - epithelial membrane antigen; GFAP - glial fibrillary acidic protein.

Keywords: immunohistochemistry, meningioma, ear.